Alexandre Dos Santos, Magali Court, Valérie Thiers, Sokhavuth Sar, Catherine Guettier, et al.. Identification of cellular targets in human intrahepatic cholangiocarcinoma using laser microdissection and accurate mass and time tag proteomics.: Novel cellular targets in human intrahepatic cholangiocarcinoma. Molecular and Cellular Proteomics, American Society for Biochemistry and Molecular Biology, 2010, 9 (9), pp.1991 
Introduction
Cholangiocarcinoma (CCA), which arises from the hepatic bile ducts, is the primary cancer accounting for ~10-15% of all hepatobiliary malignancies. CCA is categorized by the International Classification of Diseases for Oncology into intrahepatic and extrahepatic forms, the latter including perihilar, hilar and distal bile duct CCA. Global incidence rate of intrahepatic cholangiocarcinoma (ICC) has increased by 2-6% during recent decades, while annual incidence rate of the more common, extrahepatic form has remained relatively stable (1, 2). The diagnosis of ICC remains particularly challenging since the disease can mimic metastasis to the liver or hepatocellular carcinoma (HCC). The only potentially curative treatment options available at present are surgical.
Unfortunately, the majority of patients are diagnosed at an advanced, unresectable stage because of the initially silent clinical characteristics of this malignancy. The prognosis of ICC is therefore devastating, with survival of less than 24 months following diagnosis. Although several risk factors have been reported as contributing to the development of the disease, most cases of ICC occur in the absence of known etiological factors (3) (4) (5) . As a consequence, considerable efforts have been made to identify reliable markers to enable the early detection of biliary cancers and provide new insights into the pathogenesis of this deadly disease (6) . Recent studies have focused on the cytokines and growth factors (7, 8) produced by CCA cells, as well as on the proteomic analysis of serum and bile (9, 10) . Follow-up studies are ongoing to determine the sensitivity and specificity of the markers that have emerged from these investigations.
Tumor tissue is undeniably the most appropriate resource to investigate tumor-specific signals.
Indeed, the determination of alterations to the protein profiles of ICC may offer opportunities to identify tumor-specific markers. To date, proteomics studies performed using tumor tissues have mainly tried to identify proteins with a differential expression between HCC and ICC in order to prevent the misclassification of these pathologies (11, 12) . Furthermore, these studies, performed on total liver homogenates, were not appropriate to detect proteins with altered expression in tumorous cholangiocytes. Indeed, ICC tumor cells are essentially embedded in an abundant stroma containing inflammatory cells and fibroblasts, which may impair the detection of proteins displaying tumorspecific expression patterns (13) . In summary, because no proteomics studies have so far been performed on isolated cholangiocytes, any proteome alterations in the setting of ICC remain a matter of speculation.
Laser microdissection (LM) has emerged as a suitable tool to selectively extract cells of interest from their natural environment. This technology has been employed extensively to profile global gene expression in purified tumor cells (14) (15) (16) . It has also been used successfully in experiments designed to discover protein biomarkers through mass spectrometry-based proteomics studies (17) (18) (19) . However, working with such small samples challenges conventional proteomics techniques in terms of sensitivity and the precision of quantitation.
One particularly efficient method for proteome analysis is the so-called Accurate Mass and Time (AMT) tag approach, where high performance liquid chromatography (HPLC) and high resolution Fourier transform ion cyclotron resonance mass spectrometry (FTICR-MS or FTMS) work in synergy to achieve a broad proteome coverage, even for small sample amounts (20, 21) . A recent report demonstrated the significant advantage of the AMT tag method over more conventional proteomics technologies in enabling significantly broader proteome coverage using the minute protein quantities available from tissue microdissection (22) .
In the present study, we used an AMT tag strategy to determine the differential protein profile between tumorous and non tumorous microdissected cholangiocytes, in order to define specific proteome alterations of human ICC. Among proteins with altered expression in ICC, we detected a panel of proteins conforming to potential tumorigenic pathways which could be candidates as therapeutic targets and tumor markers for this lethal disease.
Experimental Procedures -Patients and tissue samples
Liver specimens were obtained from the "Centre de Ressources Biologiques Paris-Sud", Paris-Sud University, France. Access to this material was in agreement with French legislation. Tissue samples were collected at the time of surgical resection with the prior informed consent of patients.
The local research ethics committee specifically approved this procedure. Detailed clinical data regarding these subjects are summarized in Table 1 . Tumorous and adjacent non-tumorous hepatic tissues from four patients with intrahepatic cholangiocarcinoma and five perihilar samples containing large bile duct sections from control subjects without ICC, were obtained within 30 minutes of surgical resection. These samples were immediately frozen in liquid nitrogen and stored at -80°C until use. The tumors were graded by a pathologist by means of microscopic examination.
-Laser microdissection (LM)
The liver sections were prepared and treated as previously described (23) . LM was performed using a PALM Microbeam system (Carl Zeiss Inc.) (see Supplementary Figure 1) . From each liver sample, approximately 100,000 cells corresponding to 10 mm 2 were microdissected and catapulted directly into the cap of a microcentrifuge tube containing 10µl 10% SDS. Cell lysates were stored at -80°C until use. Based on a careful review, each section was estimated to contain ≥90% of the desired cells.
-Mass spectrometry analysis
1-Sample preparation
For AMT tag database generation, LC-MS/MS analyses have to be performed on fractionated samples to achieve decent proteome coverage. For this purpose, four to six samples were pooled per pair of patients with or without ICC ( Figure 1A ). Thirty microliters of lysis buffer (50mM Tris pH 6.8, 2% SDS, 0.35M beta-Mercaptoethanol and 4M urea) were added to each pool and the samples were deposited on a 1D-SDS-PAGE gel before being subjected to a short separation (pseudostacking) in order to prevent the sample from being distributed over the whole gel lane. After
Coomassie Blue staining to reveal proteins, each pseudo-stacking band was cut into 8 slices and the corresponding fractions were digested in-gel with trypsin (Promega, Charbonnières-les-bains, France), as described previously (24) . An estimated 0.8 to 1.2 µg of total protein was injected for each gel fraction. All fractions were analyzed with LC-MS/MS in triplicate and the resulting peptide identifications were used to compile an AMT tag database.
For quantitative studies, protein extracts from individual patient biopsies were deposited on 1D-SDS-PAGE gel and migrated in the stacking mode ( Figure 1B ). The stacked gel band associated with each patient was then excised and digested in-gel as described above. The resulting peptide mixtures were analyzed in triplicate using LC-FTMS. Peptides from approximately 20,000 cells were injected for each LC-FTMS analysis.
2-nano-HPLC-MS and MS/MS analysis
All proteomic analyses were performed using the 7-tesla hybrid linear ion trap Fourier transform ion cyclotron resonance mass spectrometer LTQ-FT Ultra (Thermo Electron, Bremen, Germany) coupled to an Ultimate 3000 (LC-Packings, Amsterdam, Netherlands) nano HPLC system mounted with an LC-Packings Pepmap nano-column (75 µm ID, 15 cm long, 3 µm particles, 100 Ǻ pores).
The chromatographic separation conditions were as described previously (25) .
2.1-AMT tag database generation (MS/MS mode)
The FTMS detector was used for the survey scan within the m/z range of 400-1850 at a resolution setting of 50,000 (25) . MS/MS was performed in the linear ion trap in parallel with high resolution acquisition of the MS signal on the FT detector. Dynamic exclusion prevented the acquisition of multiple MS/MS spectra for a given precursor ion (mass tolerance = ± 2 ppm, repeat MS/MS (27) . The MS identification database was then converted into an AMT tag database (Microsoft Access format) by grouping the multiple occurrences of each identified peptide. To reduce false positives, we opted for the removal of peptides with length ≤6 amino acids. In addition, only proteins covered by at least two peptides were considered for inclusion in the database, with the exception of proteins covered by a single peptide (length >6) with a Mascot score greater than or equal to 50. Peptides spectrum matches for these peptides have been compiled and are provided as supplementary figure 2.
2.2-Quantitative MS acquisitions (MS mode)
All quantitative MS data were obtained under the FTMS detection mode on an m/z range of 400-1850 and resolution of 50,000. We took advantage of the parallel acquisition capability of the LTQ-FT instrument to acquire a single MS/MS spectrum during each survey scan. This allowed us to further populate the AMT tag database without compromising the MS data acquisition rate.
MS data were processed using the Decon-2LS/VIPER open-source software suite provided by PNNL (see http://ncrr.pnl.gov/). Individual MS spectra were de-isotoped using Decon-2LS. The VIPER software then ensured LC-MS feature detection, retention time alignment and feature identification in the AMT tag database, as previously described (28) We opted to further filter the list of identifications by keeping only matches with a confidence score (i.e. SLIC score)(29) higher than 0.9.
2.3-Statistical analysis
In order to extract lists of peptides that were differentially abundant in the two cholangiocytes populations, we applied a statistical analysis to the data based on the Spectral Index (SpI) approach
proposed by Heineke and coworkers (30) . The SpI method was developed in the context of labelfree quantification using spectral counting techniques (31) . It was necessary to adapt it slightly to fit the needs of our AMT-based label-free strategy which is reliant on peptide signal extraction. To achieve this, we replaced protein spectral counts by individual peptide abundances, and instead of defining the SpI for each identified protein, we defined an Abundance Index (AbI) for each identified peptide. The AbI was thus defined as:
Where A (resp. B ) was the average abundance of a peptide in the population A (resp. B); 
3-Immunochemical analysis

3.1-Western blot analysis.
For Western blot analysis, samples from the batches of microdissected cholangiocytes were run on SDS-PAGE and transferred onto nitrocellulose membranes as previously described (23) . The membranes were then blocked with PBS/ 5% skimmed milk / 0.1% Tween 20 for two hours at room temperature before being incubated overnight with appropriate dilutions of antibodies raised against Vimentin (DAKO, V9 clone), carbonic anhydrase II (Santa Cruz Biotechnology) and profilin-1 (Cell Signaling Technology). The primary antibody was detected using appropriate horseradish peroxidase-coupled secondary antibodies and the ECL plus kit (GE Healthcare) for signal visualization.
3.2-Construction of tissue microarray
The 
3.3-Immunohistochemical analysis
Immunohistochemical analysis was performed using formalin-fixed and paraffin-embedded tissue specimens that were matched with the samples used for LM. Deparaffinized 4-micrometer thick sections were treated with primary antibodies against vimentin and carbonic anhydrase II overnight at 4°C after appropriate antigen retrieval treatment. Primary antibody/antigen binding was detected using the Vectastain ABC system (Vector Laboratories). Nuclei were counterstained with hematoxylin. Labeling specificity was determined by omitting the primary antibody during the experiment. Using the same procedure, labeling of microarrayed tissue sections by the anti-vimentin antibody was carefully analyzed by a pathologist, and was considered to be negative when fewer than 5% of the cells of interest were immunostained. Statistical significance was calculated using a two-tailed Fisher's exact test under StatEl software (www.adscience.eu), with p< 0.01 for statistical significance.
Results
A major feature of ICC is the presence of an important stromal reaction in the tumor. Thus in order to obtain protein abundance profiles that were relevant to ICC tumor cells, we opted for the laser microdissection technique so as to collect enriched populations of cholangiocytes (see supplementary Figure 1 ). ICC tumor cells were isolated from the livers of four patients. Biliary cells dissected from large bile ducts present in the perihilar sections of the livers of five patients without ICC or any biliary tract pathology were used as controls.
Proteomics study using an AMT tag strategy
Generation of an AMT tag database
The first step in the AMT tag methodology consists in generating a database of peptides that can be identified in the sample under study. To achieve this, we analyzed peptide mixtures resulting from digestion of the various fractions obtained from pools of microdissected cells separated on 1D gels (see Figure 1A ). Following LC-MS/MS analysis and Mascot search, peptide identifications were compiled in a so-called AMT tag database. Only proteins identified by at least two peptides were considered for inclusion, except when a single peptide had a Mascot score higher than 50. In total, 21,902 peptide identifications were validated and grouped by sequence, molecular weight and average retention time. The median Mascot score for the peptides that passed our filtering criteria for inclusion in the AMT database was 50.56, and 90% of the peptides considered scored higher than 33.27. The resulting AMT tag database thus contained 2,499 distinct peptides indicative of 4,508 protein accessions. When shotgun approaches are used for protein identification, a certain degree of redundancy can be observed in the list of proteins identified. Indeed, several proteins in our database, and particularly isoforms or sequence variants, were covered by the same sub-sets of peptides. In order to reduce this redundancy in the protein list, proteins characterized by the same sub-set of peptides were grouped into so-called protein groups (32) . Supplementary Table 3 lists the 574 protein groups thus identified, and the individual proteins within these groups. This list can be considered as the minimal list of proteins required to account for all the peptides identified. In fact, the average peptide coverage for the 574 proteins incorporated in the AMT database was of the order of five peptides per protein.
The sub-cellular localization of identified proteins was determined using Ingenuity Pathway Analysis software (http://www.ingenuity.com). As shown in supplementary figure 3, while the majority (67.4%) of the proteins identified were from the cytoplasm, notable proportions (18.4% and 6.5%) arose from the nucleus and plasma membrane respectively. Overall, most sub-cellular compartments were represented in the AMT database, suggesting that our approach enabled access to a broad cross-section of cellular proteins.
Label-free quantitative LC-FTMS data evaluation
After compiling the AMT tag database, we then considered the quantitative data obtained by LC-FTMS analysis of individual microdissected samples (see Figure 1B) . Following data acquisition, several tests were performed to assess their quality. This was achieved by evaluating the raw signals in all analyses using dedicated software, and by calculating correlations between the peptide abundances obtained by different acquisitions. The Chaorder software (33) was used as a first means of data evaluation. This algorithm based on a score that measures the similarity between pairs of mass spectra enables an assessment of reproducibility and similarity between LC-MS experiments. For this purpose, Chaorder computes a pseudo-distance between acquisitions based solely on the raw signal. According to Prakash et al. (33) , a distance between two points between 0 and 0.2 represents levels of reproducibility usually seen in repeat experiments with the exact same experimental setup. Figure 2A shows the Chaorder plot obtained by comparing the LC-MS acquisitions collected during our experiment. Given the randomized order in which analyses were performed, the limited scattering of replicate acquisitions of the same sample was indicative of an absence of significant drift in the analytical system. Data consistency was further evaluated using pairwise correlations of peptide abundances between acquisitions. The higher the Pearson coefficient, the more alike the two datasets were. When plotting the correlation matrix of all experiments (see Figure 2B ), it became clear that triplicate experiments on the same subject always resulted in strongly correlated abundances (R = 0.94 ± 0.04).
Determination of deregulated proteins
Before statistical analysis, triplicate acquisitions of the same sample were combined by averaging the abundances in all runs for each peptide that had been detected at least in two of the three replicates. This procedure produced four cancer and five control datasets (see supplementary Table   4 ). During the quantitative study, we were able to detect and quantify approximately 1850 of the 2,499 previously sequenced peptides corresponding to 349 proteins identified by at least two peptides.
The nine datasets were subjected to statistical analysis, based on the approach proposed by Heineke and coworkers (30) . This method combined the relative species abundance and the number of cases within a group for which the species was detected into a so-called "Abundance index" (AbI). peptides (corresponding to 16 proteins) with higher abundance in these cells (see Table 2 ).
With respect to functional considerations, most proteins identified with an altered expression in tumorous cells could be grouped in two categories: A first pool of proteins was associated with metabolic pathways (glycolysis, neoglucogenesis or fatty acid metabolism), and a second consisted of proteins involved in cell structure and/or motility.
It is worth noting that only peptides detected at least once in each population (ICC and controls) are amenable to this type of statistical analysis. As a matter of fact, several peptides were detected only in one of the two populations. When assigning these peptides to proteins, it turned out that several proteins exclusively covered by population-specific peptides were involved in biological process relevant to carcinogenesis (see supplementary Table 5 ). Among them, the up-regulation of 
Confirmation of proteomics findings
Western blot and immunohistochemistry on matched samples.
In order to verify the reliability of the data obtained during this study, the expression of vimentin, profilin1 and carbonic anhydrase II (CAII) was assessed using Western blot in microdissected cholangiocytes from the patients and controls included in the proteomic analysis. As determined during mass spectrometry analysis ( Figure 4A ), the expression of vimentin and profilin1 was stronger in ICC samples, whereas the immunolabeling of CAII was reduced in these samples when compared with the controls ( Figure 4B ). 
Discussion
To our knowledge, this is the first study to investigate the proteome alterations that occur in ICC while taking account of the important cellular heterogeneity of this tumor. Our strategy combining LM to select cholangiocytes, and an AMT tag proteomics methodology appropriate for the analysis of small cellular samples, was devised to overcome this challenge. And indeed, this strategy provided strong evidence of specific alterations to glycolysis and organization of the cytoskeleton, two protein networks involved in carcinogenesis.
ICC is a devastating cancer with an incidence increasing worldwide. For this reason, studies have been carried out in recent years to clarify the mechanisms underlying the development of this cancer, with the aim of developing novel therapeutic strategies. These investigations provided evidences that ICC was associated with genetic alterations (38-40) and impaired protein expression that could contribute to the proliferation of tumorous cholangiocytes (41, 42) . Until now, global genome and proteome alterations in ICC have been the subject of little investigation. In particular, proteome impairments in ICC had only been explored during one study using liver homogenates (43) . Indeed, the accurate determination of proteome alterations in ICC is a particularly challenging task, because in most tumors, cholangiocytes are embedded in an abundant stroma that may mask cholangiocyte signals. Therefore, in order to obtain accurate insights into proteome alterations in ICC, we used LM to selectively extract cholangiocytes from liver specimens.
Another important prerequisite to this study was the choice of a proteomics technique appropriate for the analysis of small samples. An AMT tag strategy was adopted because this method had been shown to significantly improve proteome coverage for samples originating from microdissected breast carcinoma cells (22) . In order to exploit each specimen to the maximum, we used microdissected cholangiocytes both for the generation of the AMT tag database and the quantitative study. The resulting AMT database contained 2,499 distinct peptides belonging to 574 proteins, 460 of these being characterized by at least two peptides.
The first step in quantitative data processing consisted in assessing data quality using two independent methods: Chaorder and pairwise correlations. As can be seen from the Chaorder plot (Figure 2A) , and the pairwise correlation matrix ( Figure 2B ), acquisitions corresponding to the same patient displayed less dispersion, respectively better correlations, than analyses of unrelated samples, even though the run order was randomized. Moreover, acquisitions corresponding to the controls tended to display better homogeneity than those of cancer patients. The Chaorder plot and the correlations between replicates thus confirmed that our data were consistent with samples classification and that no outlier run was present.
We then proceeded to extract the list of peptides that were differentially abundant between the two populations using an abundance index (AbI) methodology. The observed AbI distribution was skewed toward positive values (see Figure 3A) , suggesting that the abundance of peptides in tumorous samples was slightly higher than in the control samples. Taking account of this observation, we therefore considered the median AbI value (0.140) as the reference point at which there was no difference between cancer and control samples. Statistical processing and the subsequent filtering of proteins for which no proteotypic peptides were found to be deregulated led to a list of 23 proteins with decreased abundance in ICC and 16 proteins exhibiting higher abundance in tumor cells (see Table 2 ). We believe that the rigorous criteria chosen to perform this proteomic study warrant a high level of confidence in the final list of deregulated proteins. Indeed, using alternative methods (Western-blot and immunohistochemistry), the altered expression of some of them (vimentin, profilin 1 and CAII ) could be confirmed in tumorous cholangiocytes (see Figure 4 ).
Many of the altered proteins in tumorous cholangiocytes were involved in glycolysis and regulation of the cytoskeleton. As previously observed in kidney and pancreatic cancers (44, 45) , we detected an increased abundance of proteins from the glycolytic pathway in ICC. In addition to M2-PK, we were able to identify fructose bisphosphate aldolase A and lacticodehydrogenase A. (48) (49) (50) (51) (52) . We also demonstrated the impaired expression of a group of proteins implicated in the equilibrium between globular and filamentous actin. This process, altered during cell transformation (53, 54) , is involved in cell motility, which is notably increased during invasion and metastasis (55, 56) . We found an increase in the abundance of actin-binding proteins (Cofilin1, Profilin1, Transgelin2). Cofilin1 had been reported as being over-expressed in gastrointestinal endocrine tumors, and the aggressiveness of these tumors had been linked with the expression of this protein (57) . As for Profilin1 and transgelin2, a contrasting expression pattern had been reported in breast and colon cancers (58, 59) . The functional significance of these differences needs to be clarified, particularly since these proteins had been described as tumor suppressors (60, 61) .
We also observed an over-abundance in ICC of S100A11 (Calgizzarin), a protein involved in the Ca ++ signaling network and in the regulation of cell growth and motility (62, 63) . Such alterations had also been reported in pancreatic (64) and colon cancers, where disease progression correlated with the abundance of this protein in tumor tissues. (65, 66) .
On the other hand, annexins exhibited lower abundance in our ICC samples compared to the controls. Increased expression of annexins had been reported in different types of carcinoma, e.g.
colorectal, bladder, pancreatic, hepatocellular and renal carcinomas (67) (68) (69) (70) (71) . However, a reduced expression of annexin A2, also observed in head and neck squamous cell and prostate carcinomas (72, 73) and osteosarcoma (74) , had been linked to the aggressive behavior and metastatic potential of these tumors.
Similarly, as reported in renal carcinoma (75), we observed that the catalytic subunit alpha 1 of Na/K ATPase was under-represented in ICC samples. Na/K ATPase had been reported as regulating carcinoma cell motility (76) and had been shown to be involved in tight junction formation during the biogenesis of polarized cells (77) . It has thus been speculated (75) that reduced Na/K ATPase activity might be implicated in the loss of cell-cell adhesion.
Cancer cells attain the migratory and invasive capacities required for metastasis by undergoing a phenotypic conversion referred to as the Epithelial to Mesenchymal Transition (EMT) (78) . The expression of TGFbeta, a potent inducer of EMT (79) is increased in many human cancers (80) including ICC (81, 82) . Interestingly, the protein alterations found in tumorous cholangiocytes (present study) displayed striking similarities with those reported in A549 human lung adenocarcinoma cell line (83) during TGFbeta-induced EMT. Specifically, similar impairments of vimentin, M2-PK, cofilin1, transgelin 2, Na/K ATPase and S100A11 expression were observed in both cases, suggesting that the protein profile of tumorous cholangiocytes fits with that of epithelial cells displaying a transition to the mesenchymal phenotype.
Vimentin is a mesenchymal marker that had been reported to be over-expressed in a number of cancers, its expression being associated with EMT (78) . During the present study, were able to confirm using tissue microarrays that the over-expression of vimentin was a typical feature of ICC CCA. As previously shown by Guedj et al. (84) , this tends to confirm that hilar CCA and ICC are distinct entities displaying specific protein abundance profiles. Similarly, vimentin expression was not found to be a common feature in HCC: it was only expressed in one out of the 18 tumor tissue samples analyzed. Overall, these findings suggest, as reported in others cancers (44) (45) (46) (47) (48) , that vimentin could play a role in aggressiveness of ICC and provide a basis for the serious outcome of this cancer.
Conclusion
Until now, owing to the important cellular heterogeneity of ICC, the specific protein profile of these tumors could not be adequately determined. In the present study, we selected an appropriate strategy based on LM and AMT tag proteomics, in order to access specific cellular populations and analyze their proteome with high sensitivity. We were thus able to describe a panel of 39 proteins showing altered abundance profiles in tumorous vs. healthy cholangiocytes. Most of the proteins displaying perturbed abundances had not yet been described in the setting of ICC. Interestingly, a majority of deregulated proteins were involved in glycolysis and cytoskeleton plasticity/cell motility, pathways that had been reported to be implicated in carcinogenesis. While further experiments are required to characterize the consequences of these deregulations, we anticipate that these data may open the way to novel therapeutic targets or diagnostic tools. In particular, achieving a specific diagnosis of ICC among other primary liver cancers is often problematic. Results from our tissue microarray experiment suggest that vimentin, in combination with other markers, might prove useful as an indicator of particular subtypes of ICC. This will be the subject of a follow-up study on a larger number of patients with ICC, hilar CCAand HCC.
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